Journal of Clinical Pathology · 2011 · 22 citations · 11 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer ProgressionCytotoxic ChemotherapyGenotoxic CarcinogenesisMalignant NeoplasmsOvarian CancerOvarian Cancer PharmacotherapyBrca MutationsBrca2 DeficiencyBrca2 InactivationOvarian Cancer ChemotherapyPlatinum CompoundsPlatinum SensitivityRelapse-free SurvivalSensitivity
Late-stage ovarian carcinoma is almost universally fatal. BRCA mutations are associated with an improved outcome and enhanced sensitivity to platinum chemotherapy, yet recurrence and platinum resistance remain a major problem and highly effective regimens following platinum failure do not yet exist. Here we report a remarkable case of cure following platinum-resistant stage III ovarian carcinoma in a woman with a BRCA2 mutation. The patient was subsequently treated with oral melphalan therapy and has not recurred in over 25 years. Melphalan is a bifunctional alkylator that creates inter- and intra-strand DNA cross-links. In a pharmaceutical screen, melphalan was shown to be selectively toxic to BRCA2-deficient breast cancer cell lines and produced a longer relapse-free survival in mice than did cisplatin or olaparib. There is increasing evidence to consider BRCA mutation status when selecting chemotherapy regimens, and melphalan treatment for BRCA-related ovarian cancer merits further investigation. Focusing attention on long-term survivors may provide new mechanistic insights into the biology of chemo-responsiveness.
11
Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, Beth Y. Karlan et al. · Journal of Clinical Oncology · 2010 · 488 citations · Full text
Bryan T. Hennessy, Kirsten M. Timms, Mark Carey et al. · Journal of Clinical Oncology · 2010 · 373 citations · Full text
Angela Chetrit, Galit Hirsh‐Yechezkel, Yehuda Ben‐David et al. · Journal of Clinical Oncology · 2007 · 320 citations · Full text